Authors

Yan Zou, Qinhong Zheng, Xilin Wu, Xiaoling Che#

Departments

People's Hospital of Quzhou, Quzhou, PR China

Abstract

Objective: To study the effects of capecitabine or Tegafur Gimeracil Oteraci combined with oxaliplatin on patients with advanced colon cancer and their effects on serum IL-2, TNF-α, INF-γ and miR-141 levels. 

Methods: A total of 100 patients with advanced colon cancer admitted to our hospital were enrolled and were divided into the capecitabine group and the Tegafur Gimeracil Oteraci group according to random number table method, each 50 cases. Patients in the capecitabine group were treated with capecitabine plus oxaliplatin, and the Tegafur Gimeracil Oteraci group was treated with Tegafur Gimeracil Oteraci combined with oxaliplatin. Three weeks were a course. Two courses were performed for patients in the two groups. The clinical efficacy of the two groups with different chemotherapy regimens and the effects of serum IL-2, TNF-α, INF-γ and miR-141 levels and adverse reactions were analyzed. 

Results: After chemotherapy, the ORR (54%) and DCR (86%) of the Tegafur Gimeracil Oteraci group were higher than those of the capecitabine group (ORR (44%) and DCR (78%), but the differences between they two were not obvious(P>0.05); Capecitabine or Tegafur Gimeracil Oteraci combined with oxaliplatin had more adverse reactions in patients with advanced colon cancer. Comparison between two groups, Capecitabine combined with oxaliplatin were more likely to cause adverse reactions such as digestive symptoms and hand-foot syndrome (P<0.05). 

Conclusion: Capecitabine combined with oxaliplatin are more likely to cause adverse reactions than the Tegafur Gimeracil Oteraci group, but both have significant efficacy in patients with advanced colon cancer, and may effectively lower serum IL-2, TNF-α, INF-γ and miR-141 levels of patients, increase response rate after chemotherapy and thus promote life quality.

Keywords

Capecitabine, tegafur gimeracil oteraci, oxaliplatin, advanced colon cancer, clinical efficacy, TNF-α, miR-141.

DOI:

10.19193/0393-6384_2019_6_484